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Atype1cytokine-dependentproinﬂammatoryresponseinducingclassicallyactivatedmacrophages(CaMφs)iscrucialforparasite
control during protozoan infections but can also contribute to the development of immunopathological disease symptoms. Type
2 cytokines such as IL-4 and IL-13 antagonize CaMφs inducing alternatively activated macrophages (AaMφs) that upregulate
arginase-1 expression. During several infections, induction of arginase-1-macrophages was showed to have a detrimental role by
limiting CaMφ-dependent parasite clearance and promoting parasite proliferation. Additionally, the role of arginase-1 in T cell
suppression has been explored recently. Arginase-1 can also be induced by IL-10 and transforming growth factor-β (TGF-β)o r
even directly by parasites or parasite components. Therefore, generation of alternative activation states of macrophages could limit
collateral tissue damage because of excessive type 1 inﬂammation. However, they aﬀect disease outcome by promoting parasite
survival and proliferation. Thus, modulation of macrophage activation may be instrumental in allowing parasite persistence and
long-term host survival.
1. Macrophage Diversity
Macrophages are innate immune cells that play an indis-
pensable role in the primary response to pathogens but
also they play a role in the resolution of inﬂammation and
tissue homeostasis. They can be polarized by the microen-
vironment to mount speciﬁc functions, as a consequence
they represent a group of heterogeneous immune cells. The
ﬁrst indication of macrophage heterogeneity was showed
by Gordon and colleagues during their studies of mannose
receptor (MR) regulation in IL-4-treated Mφ [1]. They
demonstrated that macrophage treatment with IL-4 induced
an alternative activation phenotype diﬀerent to the classical
macrophage activation (CaMφ), known to be dependent on
interferon-γ (IFN-γ) and tumor-necrosis factor (TNF) [2–
4].GordonlaterincludedtheeﬀectsofIL-13inthedeﬁnition
of alternative activation because IL-13 shares a common
receptor chain with IL-4 and exerts similar eﬀects on
macrophages [5]. However, the name “alternative activated
macrophages, (AaMφ)” may have led to some confusion
because it implicates that it is the only other way that
macrophages can be activated. In fact, Mosser and colleagues
showed later that this was the case. They demonstrated
that macrophage treatment with classic stimulus, like LPS
or IFN-γ, in the presence of immune complexes induces
the generation of a cellular type diﬀerent from the CaMφ.
These cells release large amounts of IL-10 inhibiting the IL-
12synthesis.TheseMφ havebeendenominated“Type2Mφ”
(T2a Mφ) because they favor the development of type II
adaptative immune response [6, 7].
In 1999 Goerdt and Orfanos proposed a classiﬁcation of
activation phenotypes based on grouping all activators other
than IFN-γ and LPS/microbes into a common alternative
activation group [8]. However, nowadays the classiﬁcation
has been extended. It has been proposed that a categoriza-
tion in which M1 polarization included classical activated
macrophages, while M2 polarization, mainly associated with
antiparasitic and tissue repair programs, was subdivided in
M2a or alternatively activated macrophages: M2b, corre-
sponding to type II activated macrophages and M2c, which2 Journal of Biomedicine and Biotechnology
includes heterogeneous macrophage deactivation stimuli
such as glucocorticoids and TGF-β [9–11]. All of these types
of macrophages can be found in a variety of immuno-
logical conditions, such as immune responses to diﬀerent
pathogens, tumors, and autoimmune diseases. Therefore,
Mosser and colleagues propose a macrophage classiﬁcation
based on the fundamental macrophage functions such as
host defense, wound healing, and immune regulation [12].
However, it is diﬃcult to say which way is the best for
classifying them. First, there are no speciﬁc biochemical
markers to assign to each population. Second, it has been
demonstrated that macrophages “sequentially” change their
functional phenotype in response to microenvironmental
changes. Therefore, macrophages can exhibit, at the same
time, diﬀerent kinds of markers associated with other types
of macrophages [13, 14]. The plasticity of macrophages
and high complexity of the in vivo environments result
in the induction of various types of macrophages during
protozoan infections and diﬀerentially aﬀect the course of
disease. Therefore, as a matter of simplicity, we will use the
terms CaMφ and AaMφ. In this review we will focus on
the relevance of arginase-1, an enzyme expressed in AaMφ,
in parasitic infection and how the arginase-1 expressing
macrophages can be exploited by parasites. In addition, we
will discuss the T cell suppressive activity of these cells and
some of the complex intracellular mechanisms involved in
the induction of this enzyme.
2.Arginase-1versusiNOS
CaMφs have on enhanced ability to present antigens and
eliminate intracellular pathogens. The antimicrobial actions
have been attributed to the nitric oxide (NO) release and
also to the synthesis of several products of NO reaction,
such as peroxynitrite [15]. NO is produced from L-arginine
by the inducible isoform of Nitric Oxide Sinthase (iNOS)
enzyme [16]. iNOS is induced in macrophages through the
inﬂammatory cytokines such as TNF-α,I F N - γ, and IL-12
[17].
DuringinfectionswithprotozoanparasitessuchasLeish-
mania, Plasmodium,o rTrypanosoma,a nI F N - γ-dependent
proinﬂammatory response triggering the development of
CaMφs is required to control parasitemia, especially during
the acute phase of infection [18–21]. Therefore, CaMφsa r e
essential components of host defense, but their activation
must be securely controlled because the cytokines and
mediators that they produce can lead to host-tissue damage.
On the other hand, depending on parasite virulence, host
genotype and stage of infection, hosts can also produce type
2 anti-inﬂammatory immune responses which aﬀect disease
outcome [22, 23].
Type 2 cytokines such as IL-4 and IL-13 antagonize
CaMφs inducing arginase-1 expression in macrophages
[24], a prototypic alternative activation marker in mouse
macrophages [10]. The expression of arginase-1 induces
a shift of arginine metabolism from NO production via
iNOS toward production of L-ornithine, a precursor for
polyamines and collagen, thereby contributing to the pro-
duction of the extracellular matrix important for wound
healing [8, 25]. Although the term “alternatively activated”
macrophages has been indicated for IL-4 and IL-13, stim-
ulated macrophages [10] factors such as IL-10 or TGF-β
[5] and phagocytosis of apoptotic cells [26] also antagonize
CaMφs and induce alternative, non-M1 activation states in
macrophages.
AaMφs in normal conditions, have been identiﬁed in
tissues in which it is necessary to avoid the inﬂammation,
such as lung and placenta [8, 27]. In addition, it was demon-
strated an increase in arginase activity in peripheral blood
of pregnant women and in term placenta [28]. Moreover,
these macrophages have been identiﬁed during the phase of
remission of acute and chronic inﬂammatory reactions like
in psoriasis and rheumatoid arthritis [29, 30]. Therefore,
generation of AaMφs after inﬂammation would favor the
maintenance of homeostasis. Nevertheless, several evidence
obtained during diﬀerent infections indicate that IL-4/IL-
13-dependent AaMφs exacerbate disease by limiting CaMφs-
dependent parasite clearance and promoting parasite prolif-
eration [31, 32]. Therefore, the successful elimination of an
infectious agent depends on the existence of temporary and
spacesignalsthatregulatethetypeofmacrophageactivation.
3. Arginase-1ExpressingMacrophages in
Helminth Infections
Helminths are worm parasites that represent a common
infectious agent in developing countries. Protection against
helminths depends on IL-4 and IL-13. However, when the
infection progress to a chronic stage, Th2 cytokine results
in AaMφs recruitment, which leads to ﬁbrosis and T cell
suppression [33–36]. During Brugia malayi experimental
infection, it has been observed that the IL-4-dependent
macrophage recruitment actively suppress the proliferation
of lymphocytes [37]. In addition, in a model of cysticercosis,
Taenia crassiceps infected mice showed a Th1 response in
early stages of the infection, which is replaced by a Th2
in the chronic stage [35]. In contrast to other helminths
infections, CaMφs are important for the clearance of T.
crassiceps [35]. However, in chronic stages, the Th2 response
results in AaMφs, that exhibit arginase activity [33]. It have
been reported that carbohydrates present in T. crassiceps
can produce the detrimental change from Th1 response
towards Th2 during this infection [38]. Besides, it was
demonstrated that previous infection of mice with the T.
crassiceps favors parasitemia and induces larger cutaneous
lesions during both Leishmania major and Leishmania mex-
icana coinfections. These authors postulated that helminth
infection may facilitate Leishmania installation by inducing
arginase-1 expressing macrophages [39].
On the other hand, Schistosoma mansoni infection, as
well as the other helminth infection mentioned above, leads
to the development of a Th2 cell response. Using IL-4 and
IL-13 knockout mice, Brunet and colleagues demonstrated
that the Th2 immune response is critical for the survival
during acute S. mansoni infection [40, 41]. They concluded
that the severity of the infection in the knockout mice
was due to an increase in the TNF-α and NO levels.Journal of Biomedicine and Biotechnology 3
However, when mice are persistently infected, the chronic
Th2 response becomes highly harmful contributing to the
development of hepatic ﬁbrosis and portal hypertension
[42, 43]. In addition, the Th2 response was also associated
with the accumulation of a large number of arginase-1
expressing macrophages in and around the granulomas [42]
and arginase-1 expressing macrophages in peritoneal cavity
and increased circulating polyamines [44] .T h ep r e s e n c eo f
arginase-1 expressing macrophages was originally hypoth-
esized to be involved in promoting the collagen deposit
and the ﬁbrosis hepatic through proline synthesis medi-
ated by arginase-1 [25]. However, Herbert and colleagues
demonstrated later using mice deﬁcient in AaMφs( Il4ra
−/flox;LysMcre) that the alternative macrophage activation
is essential for survival during schistosomiasis and down
modulates T helper 1 responses and immunopathology [45].
Moreover, the development of Th2-driven ﬁbrosis in those
mice S. mansoni infected appears normal [45]. Recently,
it was demonstrated that macrophage-speciﬁc arginase-1
exhibits both anti-inﬂammatory and antiﬁbrotic activities
during Th2-driven inﬂammatory responses induced by
S. mansoni [46]. The authors demonstrated that, instead
of promoting Th2-disease, macrophage-speciﬁc arginase-1
contributes to the resolution of schistosomiasis by inhibiting
CD4+Tcelleﬀectorfunction[46].ThedatashowedbyPesce
and colleagues identify arginase-1-expressing macrophage as
critical mediators of immune down-modulation in chronic
schistosomiasis [46]. Additionally, it has been also recently
demonstrated that the resistin-like molecule (RELM)α,
which is another molecule expressed by AaMφ, is also
involved in the Th2 cytokine-down modulation during the
pulmonary inﬂammation observed in schistosomiasis [47].
On the other hand, infection of mice with the natural
mouse gastrointestinal helminth parasite Heligmosomoides
polygyrus triggers a highly polarized Th2 response. Mem-
ory CD4+ T cells rapidly accumulate at the host-parasite
interface and secrete IL-4, inducing localized development
of AaMφs recruited to this site. These macrophages impair
larval parasite health and mobility through an arginase-
dependent pathway, contributing to eventual expulsion of
adult worms [48]. It has been demonstrated that Th2
responses enhance gut contractility and luminal ﬂuid secre-
tion, leading to worm expulsion [49, 50]. Furthermore,
speciﬁc inhibition of arginase activity during the infection
withintestinalnematodeparasiteNippostrongylusbrasiliensis
interfered with smooth muscle contractility and aﬀected
partially the protective immunity of the host [51]. Therefore,
arginase-1 expressing macrophages are widely induced by
helminths and they play diﬀerent roles in those infections.
4.ArginaseinProtozoanInfections
The type 1 pro-inﬂammatory response, crucial for parasite
control during the acute phase of infection with protozoan
parasites, should be carefully balanced by anti-inﬂammatory
molecules like IL-10 and TGF-β to avoid excessive collateral
damage to host tissues and cells. However, in many cases
protozoanparasitestakeadvantageofthisanti-inﬂammatory
response to persist in the host. It has been reported that
during Trypanosoma brucei infection, sustained CaMφs
could induce tissue damage, therefore mice that progress to
a chronic stage, generate a Th2 response, able to favor the
developmentofAaMφ [52].Inaddition,ithasbeenobserved
that Leishmania major has the ability to inhibit the produc-
tionofIL-12throughtheinductionofIL-10andTGF-β [53].
ThisimbalanceunderliesashiftfromaTh1toaTh2immune
response and reﬂects the susceptibility to the disease. This
environment generates AaMφ facilitating the dissemination
of the parasite in the host [54, 55]. Macrophage-IL-4
treatment previous to the infection with Leishmania major
or Leishmania infantum biases the metabolism of L-arginine
through arginase-1 towards the synthesis of polyamines,
which promote the intracellular growth of the parasite
[56]. Also, macrophage arginase-1-inhibition reduced the
growth of the parasites due to an increase in NO production
[56]. Additionally, in a mouse model of L. major infection,
arginase-1 is induced in both susceptible and resistant mice
during the development of the disease. The induction of the
host arginase-1 in both strains is mediated by the balance
between IL-4 and IL-12 and opposite to iNOS expression.
Moreover, inhibition of arginase-1 reduces the number of
parasites and delays disease outcome in susceptible mice,
while treatment with L-ornithine increases the suscepti-
bility of the resistant mice [54]. Furthermore, Kropf and
colleagues also demonstrated that arginase-1 activity and
production of polyamines are key factors in the regulation
of leishmaniasis [55]. Moreover, another indication for
the contribution of AaMφ to Leishmania susceptibility
was demonstrated using macrophage/neutrophil-speciﬁc IL-
4Rα-deﬁcient mice. Those mice showed a signiﬁcantly
delayed disease progression with normal Th2 and type 2
antibody responses but improved macrophage leishmani-
cidal eﬀector functions and reduced arginase-1 activity
[57]. Therefore, arginase-1 induction could be considered a
marker of disease in leishmaniasis.
On the other hand, a Th1 immune response, involving
IL-12, IL-18, and IFN-γ as well as NO-producing CaMφ,
favors the control of the early Trypanosoma cruzi infection
thatcausesChagasdisease[58,59].However,ifuncontrolled,
the Th1 immune response causes pathology. In this respect,
IL-4 and IL-10 have been implicated in resistance to T.
cruzi by balancing the early stage proinﬂammatory immune
environment [60, 61]. Therefore, once again, the Th2
environment could induce AaMφs and favor the installation
of the parasite in the host. Arginase-1 activity, nevertheless,
has not been necessarily induced by IL-4 during T. cruzi
infection. We have demonstrated arginase-1 induction by
the parasite component, cruzipain [62, 63]. We have showed
that mice immunization with the immunodominant anti-
gen cruzipain results in high Th2 cytokine secretion (IL-
4, IL-5, IL-10), and marginal levels of IFN-γ and IL-12
[62]. In addition, cruzipain-stimulated macrophages exhibit
increased arginase-1 activity and expression, and secrete
IL-10 and TGF-β [63, 64]. Moreover, cruzipain-activated
macrophages favor T. cruzi growth at the same extend as was
observed in IL-4-treated macrophages [63] and arginase-1-
inhibition leads to a drastic reduction in T. cruzi replication4 Journal of Biomedicine and Biotechnology
in macrophages [64]. Additionally, we found an increase in
arginase-1 activity during acute infection in BALB/c mice.
Furthermore, arginase-1 inhibition leads to a reduction
in the number of amastigotes in infected macrophages
(Stempin, et al. unpublished data). Therefore, arginase-
1 induction could favor Trypanosoma cruzi persistence in
the host as was observed during Leishmania infection.
In addition, it was demonstrated that peripheral blood
monocytes of T. cruzi infected rats are not able to produce
NO due to an increase in the arginase-1 activity [65]. The
emergence of arginase-1-expressing macrophages is further
promoted by the ingestion of apoptotic cells generated by
NO during the early stage of T. cruzi infection, and the
concomitant enhanced TGF-β secretion [26]. Therefore,
this results in a decreased oxidative burst and persistent
parasite growth in the infected macrophages because of
the down regulation of iNOS activity. Moreover, TGF-
β, by inducing ornithine decarboxylase activity, favors the
synthesis of polyamines that are essential for the intracellular
parasite replication [66]. Hence, T. cruzi might evade the
host-protective Th1 immune response mediated by CaMφs
by instructing Th2 cytokine secretion, which stimulates
AaMφ. Besides down regulating the inﬂammatory immune
response,AaMφsmightfavortheonsetofachronicinfection
during Chagas disease.
5.AlternativeActivationMarkersin
HumanandMurineMacrophages
AaMφ generation is associated with changes in macrophage
function and distinctive gene signatures. Although the
alternative activation markers for human and murine
macrophages have long been considered analogous, there
are diﬀerences between species. IL-4 and IL-13 induce genes
conserved in both species such as MHC-II, MR, MGL1/2,
and CD23 as well as divergent ones such as arginase-1,
chitinase-likemolecules(Ym1/2),andRELMαinmouse,and
nucleotide G protein–coupled receptors (GPCRs) in humans
[10, 67–69]
As mentioned before, mouse arginase-1 is a prototypic
alternative activation marker and its induction is conﬁned
mainly to murine macrophages [70]. However, it was
recently demonstrated that human mononuclear cells can
adopt an alternative activation proﬁle during the infection
with the ﬁlarial nematode parasite Wuchereria bancrofti, the
etiological agent of lymphatic ﬁlariasis [71]. The authors
demonstrated that these cells express the arginase encoding
genes and a member of the resistin family [71]. Under
the appropriate environment, this outcome would indicate
that human monocytes can undergo alternative activation,
similar to that found for mouse macrophages [72].
In addition, it was demonstrated that arginase-1 is
expressed constitutively in human granulocytes and would
participate like a new eﬀector mechanism against fungi,
decreasing arginine availability in phagolysosome [73]. In
contrast to murine arginase-1, human granulocyte arginase-
1 expression is not inﬂuenced by proinﬂammatory or anti-
inﬂammatory cytokines in vitro. On the other hand, its
location is not cytosolic but it is present in azurophils
granules and it was determined that human arginase-1
present in neutrophils has the capacity to suppress T cells
[74].
Although the general functions and behaviors of murine
and human AaMφs are thought to be preserved, the genes
required for such functions are to some extent diﬀerent.
The divergences between species and their functional
repercussion require further investigation [10].
6. Role of Arginase-1 in Immunosuppression
The ability of arginase-1expressing macrophages to suppress
T cell proliferation could explain their presence in placenta
and lung of healthy individuals [8, 75]. However, the
presence of suppressive arginase-1 expressing macrophages
duringinfectionsaswellasduringcancercouldbedetrimen-
tal for the host [76].
As was mentioned above, during Brugia malayi exper-
imental infection, it has been demonstrated that IL-4-
dependent macrophages recruited in vivo actively suppress
the proliferation of lymphocytes. These macrophages block
proliferation by cell-to-cell contact, implicating a receptor-
mediated mechanism. [37]. In addition, it was also recently
demonstrated that arginase-1 plays an essential role in the
T cell suppression observed at the site of pathology in non-
healing leishmaniasis lesions [77]. Modollel and colleagues
demonstratedthatarginase-1ishighlyexpressedatthesiteof
pathologyinnonhealinglesionsandcauseslocaldepletionof
L-arginine which impairs the capacity of T cells in the lesion
to proliferate and to produce IFN-γ,r e q u i r e df o rp a r a s i t e
killing. They clearly showed that arginase-1 is mediating T-
cell immunosuppression since its inhibition or the injection
ofL-arginine reversessuppression and resultsin macrophage
eﬃcientcontrolofparasitereplication[77].However,during
schistosomiasis, macrophage-speciﬁc arginase-1 contributes
to the resolution of the infection by inhibiting CD4+ T
cell proliferation and cytokine production. The authors
showed that arginine depletion by arginase-1 expressing
macrophages was the primary suppressive mechanism while
no signiﬁcant contribution for IL-10 or TGF-β was observed
in these studies [46]. Moreover, Terrazas and colleagues
have showed that Taenia crassiceps-induced macrophages
have suppressive T cell activity and this eﬀect was IL-10,
IFN-γ, NO independent, and cell-cell contact dependent
[36]. Taenia crassiceps-induced macrophages showed an
alternative activated proﬁle with high expression of Fizz1,
Ym1, and arginase-1 [36]. The authors demonstrated that
the suppressive ability of the Taenia crassiceps-induced
macrophages involves programmed death ligand molecules,
PD-L1 and PD-L2, which were found to be upregulated
in those macrophages [36]. These molecules bind to the
receptor programmed death 1 (PD-1) which is expressed on
activated T cells (B cells and myeloid cells also) and their
interactions result in down-modulation of T cell responses
[78, 79]. In addition, the selective upregulation of PD-L1 on
macrophages by Schistosoma mansoni worms has shown to
induce anergy of T cells during early acute stages of infectionJournal of Biomedicine and Biotechnology 5
before the subsequent emergence of egg-induced T cell
suppression in the chronic stages of infection [80]. Studies
in progress in our group demonstrated that the PD-1/PD-
L pathway may be also involved in the immunosuppression
observed during the acute phase of T. cruzi infection [81].
We observed change in the expression of these molecules
during the acute phase of T. cruzi infection in CD3+,
CD11c+, and F4/80+ peritoneal cells. In addition, T. cruzi-
m a c r o p h a g e sw e r ea b l et os u p p r e s sc o n c a n a v a l i nA( C o n A )
T cell induced proliferation which is restored by blocking
PD-1 pathway with antibodies or by inhibiting arginase-1
activity.Inaddition,ourpreliminarydatasuggestthatPD-L2
could be involved in arginase-1 induction in T. cruzi infected
macrophages (Dulgerian et al. unpublished data). Therefore,
this may suggest that PD-1-PD-Ls interaction is important
in arginase-1 modulation and in T. cruzi replication in
macrophages.
In this context, it has been recently showed that the
activity and expression of arginase-1 could be regulated by
both PD-1 and CTLA-4 on the myeloid-derived suppressor
cells (MDSCs) [82]. It has been extensively demonstrated
that increased metabolism of L-arginine by myeloid cells
can result in the impairment of lymphocyte responses to
antigen during immune responses and tumor growth [76].
PD-1 molecules expressed on MDSCs can be involved in the
regulation of MDSC function by regulating the activation
and expression of arginase-1. The regulation of arginase-
1 activity and expression by costimulatory or co-inhibitory
molecules on the MDSCs might be important in inducing
and maintaining of immunosuppression [76].
On the other hand, the role of human granulocyte
arginase in immunosuppression was explored by Munder
and colleagues [74]. They demonstrated that upon human
polymorphonucleargranulocytes(PMN)celldeath,arginase
is liberated and very high activities of this enzyme accumu-
late extracellularly during purulent inﬂammatory reactions.
PMN arginase induces a profound suppression of T cell
proliferation and cytokine synthesis. This T cell suppression
is due to arginase-mediated depletion of L-arginine in the
T cell environment, which leads to CD3ζ chain down-
regulation [74]. Recently they showed that PMN arginase-
mediated suppression reach also NK cells [83]. Granulocyte
arginase severely impairs NK cell proliferation and IL-12/IL-
18-induced secretion of IFN-γ [83].
7. SignalsInvolvedinArginase-1Induction
Oneoftheﬁrstworksthatinvestigatedabouttheintracellular
signals involved in arginase induction by LPS showed that
protein kinase A (PKA) activation was required whereas
the activation of the enzyme did not depend on PKC,
neither the intracellular levels of Ca++ [84]. Later, the
signals involved in IL-13 arginase-1-induction were studied
by Chang and colleagues [85]. They demonstrated that IL-13
down-regulates NO production through arginase induction
via cAMP/PKA, tyrosine kinase (TK), and p38 MAPK
signaling [85]. Recently ﬁndings correlate with the previous
role of PKA in arginase induction in macrophages [86]. We
have previously shown that arginase-1 induction mediated
by cruzipain involves the activation of multiple intracellular
signals such as TK, PKA, and p38 MAPK [64, 87], similar
to the signals triggered by IL-13 [85]. Furthermore, it
was demonstrated that the transcription factor STAT-6 is
required for arginase-1 induction in IL-4 and IL-13-treated
macrophages [88, 89]. However, it was recently shown that
some intracellular pathogens induced arginase-1 expression
inmousemacrophagesthroughtheTollLikeReceptor(TLR)
pathway [90]. In contrast to diseases dominated by Th2
responses in which arginase-1 expression is greatly increased
by IL-4 and IL-13 signaling through the transcription factor
STAT6, TLR-mediated arginase-1 induction was indepen-
dent of the STAT6 pathway. Speciﬁc elimination of arginase-
1 in macrophage favored host survival during Toxoplasma
gondii infection and decreased lung bacterial load during
tuberculosis infection. Therefore, TLR pathway could be also
advantageous to certain pathogens [90].
8. Concluding Remarks
The diversity of macrophage activation states is probably
as diverse as the number of environmental conditions to
provide the appropriate immune response. It is inﬂuenced
by the complexity of the stimulus, the sequence of exposure,
and the status of macrophage diﬀerentiation at the time of
exposure. In this review we have focused our discussion on
the role of arginase-1-macrophages in parasitic infections.
The outcome of protozoan infections is crucially dependent
on the order, timing, and relative strength of type 1
versus type 2 responses and CaMφ versus AaMφ generation
(Figure 1). During several infections induction of arginase-
1- macrophages was showed to have a detrimental role by
limiting CaMφ-dependent parasite clearance and promoting
parasite proliferation. Additionally, the role of arginase
in T-cell suppression has been explored recently. During
several infections, arginase-1 T cell suppression contributes
to failure to eliminate the pathogen. However, during
schistosomiasis arginase-1-expressing macrophages suppress
Th2-dependent inﬂammation and ﬁbrosis, contributing to
the resolution of the infection. Arginase suppressive activity
hasbeenmainlyassociatedwithL-argininedepletion leading
to CD3 instability. In addition, PD-1 and their ligands have
been also involved in arginase-1 suppression (Figure 2). On
the other hand, although arginase-1 induction is conﬁned
mainly to murine macrophages, it was demonstrated that
it is expressed constitutively in human granulocytes and
it showed some similar function to the murine arginase
(Figure 2). However, although the general functions and
b e h a v i o r so fm u r i n ea n dh u m a nA a M φs are thought to be
preserved, human alternative activated macrophages should
be further investigated.
Additionally, recent ﬁndings have improved the under-
standing of signals involved in arginase-1 expression. In
addition to the well-known role of STAT-6 in IL-4 and IL-
13-arginase induction, during Th1 responses, a novel TLR
dependent but STAT6-independent pathway of arginase-1
expression was identiﬁed.6 Journal of Biomedicine and Biotechnology
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Figure 1: Role of macrophage activation in parasitic infections. A type 1 cytokine-dependent proinﬂammatory response inducing classically
activated macrophages (CaMφs) leads to NO production and also to the synthesis of several products of NO reaction. CaMφs are crucial for
parasite control during protozoan infections but can also contribute to the development of immunopathological disease symptoms. Type
2 cytokines such as IL-4 and IL-13 antagonize CaMφs inducing alternatively activated macrophages (AaMφs) that upregulate arginase-1
expression. Arginase-1 can also be induced during the infection by apoptotic cells or even directly by parasites or parasite components.
Arginase-1 limits CaMφ-dependent parasite clearance promoting parasite proliferation. Additionally, arginase-1 suppresses T cell response.
Therefore, generation of alternative activation states of macrophages could limit collateral tissue damage because of excessive type 1
inﬂammation. However, they aﬀect disease outcome by promoting parasite survival and proliferation.
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Proliferation
cytokines
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L-arginine
PD-L1/2
Arginase-1
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Figure 2: Role of arginase in immunosuppression. During parasitic infections, mouse macrophage-speciﬁc arginase-1 induces T cell
suppression due to arginase-mediated depletion of L-arginine in the T cell environment, which leads to CD3ζ chain down-regulation.
Additionally, PD-1/PD-L pathway may be also involved in the T cell suppression. Furthermore, human granulocyte arginase can also
induce immunosuppression by a similar mechanism. Upon human polymorphonuclear granulocytes (PMN) cell death, arginase is liberated
and high activities of this enzyme accumulate extracellularly during purulent inﬂammatory reactions. PMN arginase induces a profound
suppression of T cell and NK cell proliferation and cytokine synthesis.Journal of Biomedicine and Biotechnology 7
Finally, our knowledge of how diﬀerent types of
macrophages aﬀect the course of infectious diseases caused
by protozoan parasites should provide therapeutic beneﬁts
in controlling these infections.
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